SMARCA2 and glioblastoma: The DNA damaging agent TMZ is frontline therapy for patients with GBM, and we previously found that the BRG1/BRM bromodomain inhibitor PFI‐3 can enhance the sensitivity of GBM cells to the anticancer activity of TMZ in vitro.25